Abpro Holdings, Inc. · OTC:ABPO

Abpro — Atlantic Coastal Acquisition Corp. II — SPAC Merger (October 2024)

43 slides from Abpro's SPAC merger presentation, Oct 15, 2024

  1. Slide 1: Corporate Presentation October 2024

    Exhibit 99.1 Corporate Presentation OCT 2024 1

  2. Slide 2: Disclaimers

    2 Disclaimers This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Abpro Corporation (“Abpro”) and Atlantic Coastal Acquisition Co

  3. Slide 3: Disclaimers: Additional Information and Where to Find It

    3 Disclaimers Additional Information and Where to Find It This document relates to the Proposed Business Combination between Abpro and ACAB. ACAB filed a registration statement on Form S-4 relating to the Proposed Business Combination (the “Registration Statement”) which will includes a proxy statem

  4. Slide 4: Table of Contents

    44 Transaction Overview Investment Highlights 1 2 Pipeline and Technology Experienced Team 3 4 Platforms Table of Lead Candidates Additional Pipeline Contents 5 6 Candidates Program Development Appendix 7 8 Timeline

  5. Slide 5: Transaction Overview

    5 Transaction Overview Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) plans to conduct a Pro Forma Valuation at Close business combination with Abpro Corporation (“Abpro“) at a purchase price of approximately $500 million (USD millions, except for share data) • Transaction expected to be funde

  6. Slide 6: Investment Highlights

    6 Investment Highlights Proprietary Antibody Platform Robust Therapeutic Pipeline of Next Generation Candidates ® • Antibody Discovery: DiversImmune Candidate Indication TM • Antibody Engineering: MultiMab • ABP-102(HER2/CD3) Breast and gastric cancer • ABP-201(VEGF/ANG2) Wet AMD and DME • ABP-110(G

  7. Slide 7: Experienced Leadership Team

    7 Experienced Leadership Team Ian Chan, MBA Robert Markelewicz, MD Eugene Chan, MD Miles Suk CEO, Co-founder Chairman, Co-founder Chief Medical Officer Co-CEO, Board Member Brown AB; Harvard MBA Brown ScB, MMSc, MD Harvard AB; Harvard MD Michigan State U, BS

  8. Slide 8: Atlantic Coastal Management Team

    8 Atlantic Coastal Management Team Shahraab Ahmad Burt Jordan Jason Chryssicas Tony Eisenberg President Chairman, CEO CFO CSO

  9. Slide 9: Experts on Boards

    99 Experts on Boards 1 2 2 Robert Langer, PhD Laurie Glimcher, MD Ron Levy, MD David H. Koch Institute Professor, MIT; Former President and CEO, Professor and Chief, Founder of Moderna, BIND, Dana-Farber Cancer Institute Division of Oncology, Momenta, AIR, others Stanford School of Medicine 2 2 2 Ge

  10. Slide 10: Pipeline with Next Generation Candidates

    10 Pipeline with Next Generation Candidates TOTAL INDICATION PROGRAM TARGET PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 PHASE 3 ADDRESSABLE MARKET 1 DME/Wet AMD Anti-VEGF/ANG2 ABP-201 $10.4 Billion Breast, Gastric 2 Anti-HER2/CD3 ABP-102 $12.1 Billion Cancer 3 Liver Cancer Anti-GPC3/CD3 ABP-110 $12.9 B

  11. Slide 11: Technology Platform

    TECHNOLOGY PLATFORM

  12. Slide 12: DiversImmune Discovery Platform

    ® 12 12 Diversimmune Discovery Platform Features: • Rapid Generation Creates antibody therapies against traditionally Proprietary antibody discovery platform difficult targets that seeks to swiftly produce a diverse array of antibodies Validated by global pharma and research institutions • Target Va

  13. Slide 13: MultiMab Antibody Engineering Platform and TetraBi Format

    TM 13 13 MultiMab Antibody Engineering Platform and TetraBi Format Anticipated Advantages of TetraBi Format: 1 Enhancing efficacy and safety: fine-tuning antibody product • Bivalent binding to TAA for potentially formats for optimal results increased efficacy • Fc modification for reducing toxicity

  14. Slide 14: Lead Programs

    LEAD PROGRAMS • ABP-102 • ABP-201

  15. Slide 15: ABP-102 HER2/CD3 T-Cell Engager

    ABP-102 HER2/CD3 T-Cell Engager Treatment for HER2+ Breast Cancer & Gastric Cancer

  16. Slide 16: ABP-102: Strategic Partnership with Celltrion

    16 16 ABP-102: Strategic Partnership Global Development & with Celltrion Commercialization Partnership Highlights Leading biopharmaceutical company headquartered in Incheon, South Korea; KRX: 068270 Fully Funded Anticipated Development Plan • Celltrion funds all development costs, including preclini

  17. Slide 17: ABP-102: Addressing Unmet Needs in HER2+ Cancers

    17 Potential benefits of Potential Competitive ABP-102 in immuno- Advantages: Addressing Unmet oncology Needs in HER2+ • Activating T cells to kill tumor cells • Current HER2-directed therapies have Cancers Treatment: demonstrated increased chemical off TetraBi antibody targets HER2 on target toxici

  18. Slide 18: ABP-102: Potent killing of HER2-high target cells in vitro

    18 18 ABP-102: Potent killing of HER2-high HER2 affinity: but not HER2-low target cells in vitro HER2 x CD3 parental TetraBi > ABP-102a > ABP-102b > ABP-102c HER2-high Runimotamab biosimilar HER2-low (HER2-null x CD3) Abpro internal data

  19. Slide 19: ABP-201 VEGF/ANG-2 Bispecific Antibody

    ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODY Treatment for Diabetic Macular Edema (“DME”) & Wet Age-related Macular Degeneration (”AMD”)

  20. Slide 20: Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201

    20 20 Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201 • We believe that ABP-201 will Competitive Landscape require less frequent dosing, providing a significant $10.4 billion advantage in the commercial Global Wet AMD market setting. 1 size projection in 2024 • We anticipate that ABP-201 wi

  21. Slide 21: ABP-201: Anti-VEGF/ANG2

    21 ABP-201: Anti-VEGF/ANG2 Target Indication: Wet AMD/DME Key Characteristics • Dual inhibition of VEGF and ANG-2 to block angiogenesis ABP-201 • Four high-affinity binding sites for increased potential potency • Dual targeting in single molecule for simultaneous inhibition • Natural antibody struct

  22. Slide 22: ABP-201: In Vivo Preclinical Models Have Positive Results

    22 ABP-201: In Vivo Preclinical Models Have Positive Results 2 Laser-induced neovascularization model in rats ABP-201 significantly reduced vascular lesions comparable to Eylea in rat models Leakage score Lesion volume Mean total ocular examination scores over 1 Mean Intraocular pressure over time 1

  23. Slide 23: ABP-201 Exhibits Favorable PK Compared with Vabysmo

    23 ABP-201 Exhibits Favorable PK Compared with Vabysmo 1 Faricimab(RG7716) 0.5 mg dose in Cyno PK parameter Unit Serum Aqueous C µg/ml 3.8 99 max t h 24 72 max t h 89.3 68 1/2 Faricimab PK in t h 672 672 last Cyno AUC (ug*h)/ml 295 18100 0-tlast AUC (ug*h)/ml 296 18200 0-inf F % 12.7 N/A vs. 2 ABP-2

  24. Slide 24: ABP-201 Current Status and Development Plan

    24 24 Current Status: • Investigation New Drug (IND) enabling studies underway Anticipated Development Plan • Q1 2026: File IND application and Initiate a Phase 1 trial in patients with ABP-201 Wet AMD Development • Following the identification of the Collaboration Highlights: Strategy maximum toler

  25. Slide 25: Additional T-Cell Engagers

    ADDITIONAL T-CELL ENGAGERS ABP-150: Anti-Claudin 18.2/ CD3 against Gastric Cancer ABP-110: Anti-GPC3/CD3 against Liver Cancer

  26. Slide 26: ABP-150: Anti-Claudin18.2/CD3

    26 ABP-150: Anti-Claudin18.2/CD3 Target Indication: Gastric Cancer $13.11 billion Global gastric cancer market Key Characteristics 1 size projection by 2029 • T-cell engager designed to fight cancer through co-targeting CD3 & Claudin 18.2 • Specific for Claudin 18.2, avoiding binding closely related

  27. Slide 27: ABP-150: In vivo Efficacy and Safety Profile in Preclinical Models

    27 ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models 1 Potent in vivo efficacy in gastric cancer ABP-150 is well tolerated in a preclinical tox model 1 xenograft mouse model Body weights Temperatures 24 38.0 ABP ABP 37.5 22 ABP Veh 2500 37.0 0.05 mg/kg ABP-150 20 36.5 0.005 mg/kg AB

  28. Slide 28: ABP-110: Anti-GPC3/CD3

    28 28 ABP-110: Anti-GPC3/CD3 Target Indication: Hepatocellular Carcinoma- Liver Cancer Designed to provide in-vitro T-cell + 2 + 2 HEP3B tumors + CD8 T cells HEPG2 tumors + CD8 T cells dependent cellular cytotoxicity 60 100 (TDCC) against liver cancer cells YP7 x CD3 YP7 x CD3 80 3BN9 x CD3 3BN9 x C

  29. Slide 29: Anticipated Clinical Development Timeline

    29 Anticipated Clinical Development Timeline Timeline 2025 2026 2026 2027 2027 2028 2028 2029 2029 2030 2030 2031 and Beyond 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H ABP-102 BLA Phase 1 Phase 2 Phase 3 BLA- ABP-201 Phase 1 Phase 2 Phase 3 2034 1H BLA- ABP-150 Phase 1 Phase 2 Phase 3 2032 2H BLA- ABP-110 Pha

  30. Slide 30: Appendix

    • Additional Data for Abpro Technology Platform • Additional Key Team Members Appendix • Additional Data for ABP-102(HER2/CD3) • Additional Data for ABP-201(VEGF/ANG2)

  31. Slide 31: Additional Data for Abpro Technology Platform

    Additional Data for Abpro Technology Platform 31

  32. Slide 32: DiversImmune Platform Case Study: Amyloid

    32 32 Diversimmune Platform Case study: Amyloid*: Preclinical results from functional therapeutic antibodies ® generated with DiversImmune platform, via a project for GSK, 1 published in Nature and The New England Journal of 2 Medicine Abpro generated a therapeutic mAb “Abp1” against Amyloid used by

  33. Slide 33: Neutralizing Antibody Discovery Platform

    33 Neutralizing Antibody B cell Cloning Discovery Platform Timeline: < 2 months Neutralizing Target-specific Paired H/L cDNA NGS B Cell isolation Activity memory B cells by barcoding sequencing Convalescent /immunized human Humanized mice subjects A strategy to enrich only the B cells that Cloning a

  34. Slide 34: Anticipated Advantages of TetraBi Format Over Earlier T-Cell Engagers

    34 Anticipated Advantages of TetraBi Format Over First- and Second-Generation T-Cell Engagers nd st 1 Generation 2 Generation Abpro Antibody Bispecific Benefit Bispecific TetraBi Characteristics Stronger binding to the tumor cell, potentially leading Bivalent Binding to to increased efficacy and an

  35. Slide 35: Additional Key Team Members

    Additional Key Team Members 35

  36. Slide 36: Additional Key Team Members

    36 Additional Key Team Members Mengsha Wang, MBA Askar Kuchumov, PhD Shaun Murphy, PhD Director of Corporate VP of Business VP of Immunology Development Development Clark U MSc. Finance, MBA Lomonosov Moscow State, BS Brown PhD, Wayne State U School of Medicine, PhD Research Harvard Medical School J

  37. Slide 37: Additional Data for ABP-102 HER2/CD3 T-Cell Engager

    Additional Data for ABP-102 HER2/CD3 T-Cell Engager 37

  38. Slide 38: ABP-102: TetraBi antibodies exhibit selectivity in vitro

    ABP-102: engineered TetraBi antibodies exhibit selectivity in vitro, with potent 38 cytotoxicity on HER2-high cell lines and reduced killing of HER2-low cell lines HER2 expression level High Intermediate Trastuzumab binding by flow cytometry results in a 1 range of HER2 expressing cancer cell lines.

  39. Slide 39: ABP-102: Functional selectivity for T cell activation

    ABP-102: engineered TetraBi antibodies exhibit functional selectivity for T cell 39 activation, including reduced cytokine release for HER2-low expressing cell lines HER2 high HER2 low ABP-102-mediated PBMC cytotoxicity of HER2-high (SKBR3) ABP-102-mediated cytokine release (IL-2, IFNg, IL-6, TNFa)

  40. Slide 40: Additional Data for ABP-201 VEGF/ANG-2 Bispecific Antibodies

    Additional Data for ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODIES 40

  41. Slide 41: ABP-201 Exhibits Favorable PK Compared with Eylea

    41 ABP-201 Exhibits Favorable PK Compared with Eylea 1 ABP-201 0.2mg dose in Rabbit PK parameter Unit Serum Aqueous Vitreous Retina C µg/ml 0.415 14.374 183.357 8.457 max t h 48 48 1 24 max t h 38 108 82 106 1/2 AUC (ug*h)/ml 52 2529 36922 1777 0-tlast AUC (ug*h)/ml 55 2557 37027 1795 0-inf MRT (h)

  42. Slide 42: Certain Risks Related to ACAB, Abpro and the Business Combination

    42 Certain Risk Related to ACAB, Abpro and the Business Combination All references to the “Company,” “we,” “us” or “our” refer to the business of Abpro Corporation. and its subsidiaries, taken as a whole, unless the context otherwise requires. The risks noted below are not exhaustive and are qualifi

  43. Slide 43: Thank you!

    Mission: Developing antibody therapies to improve the lives of patients Thank you! facing severe and life- threatening diseases https://abpro.com/ ABPRO CORPORATION IR@abpro.com 68 Cummings Park, Woburn, MA 01801

Atlantic Coastal Acquisition Corp. II — SPAC Merger (October 2024) on 6ix